Immunological investigation involving 100 estrogen-progesterone receptor negative (RE-RP-) and 71 estrogen-progesterone receptor positive (RE+RP+) breast cancer patients demonstrated that Ki-67 expression in the former group was twice (49.8%) that in the latter (25.9%). Low Ki-67 expression was found in 39% of RE-RP-tumors whereas high expression--in 28% of RE+RP+ tumors.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hormone Signaling in Breast Development and Cancer.
Adv Exp Med Biol
January 2025
Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Hormones control normal breast development and function. They also impinge on breast cancer (BC) development and disease progression in direct and indirect ways. The major ovarian hormones, estrogens and progesterone, have long been established as key regulators of mammary gland development in rodents and linked to human disease.
View Article and Find Full Text PDFCD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: Targeting the tumour inside out.
Colloids Surf B Biointerfaces
January 2025
Institute of Cancer Therapeutics, University of Bradford, Bradford, Richmond Rd, Bradford BD7 1DP, United Kingdom. Electronic address:
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer defined by the lack of three key receptors: estrogen, progesterone, and HER2. This lack of receptors makes TNBC difficult to treat with hormone therapy or drugs, and so it is characterised by a poor prognosis compared to other kinds of breast cancer. This study explores photoactive Poly(lactic-co-glycolic acid) (PLGA) nanoparticles as a potential therapeutic strategy for TNBC.
View Article and Find Full Text PDFQuantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
Article Synopsis
- This study focused on detecting Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 in breast cancer to help categorize the disease and guide treatment choices.
- Researchers compared two preservation methods for breast tissue samples: traditional formalin fixation and RNAlater, utilizing Immunohistochemistry (IHC) and Quantitative Polymerase Chain Reaction (qPCR) for analysis.
- Findings revealed that ER and PR were positive in 60% of samples, while HER-2 was positive in only 25%, with no significant statistical difference between the results from the two preservation methods.
An Unusual Cause of Inguinal Mass in a Patient with Urolithiasis: A Case Report of Deep (Aggressive) Angiomyxoma in a Male Patient.
Clin Pract
December 2024
Department of Urology, University Hospital of Patras, 26504 Patras, Greece.
Deep or aggressive angiomyxoma is an uncommon neoplasm of the pelvis. Although deep angiomyxoma is a benign tumor, its tendency to infiltrate soft tissues and reach a large size (typically > 10 cm) indicates aggressive biological behavior. It is usually present in female patients, but there have been recent reports of male-aggressive angiomyxoma.
View Article and Find Full Text PDFMisclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.
Cancer Causes Control
December 2024
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Article Synopsis
- The SEER registry uses criteria like laterality and histology to distinguish between second primary breast cancers, affecting how accurately tumors are classified.
- Analysis of receptor status in a large sample of contralateral and ipsilateral tumors indicated that ipsilateral tumors may actually be recurrences due to their higher receptor dependence and younger patient demographics.
- While SEER's criteria enhance specificity, they may also lead to inaccuracies in classifying tumors, highlighting the need for better datasets to compare classification methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!